The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Acute Myeloid Leukemia Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
The global Acute Myeloid Leukemia Treatment market size is expected to reach US$ 1040.9 million by 2029, growing at a CAGR of 7.9% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Myeloid Leukemia Treatment in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Acute Myeloid Leukemia Treatment market. DC Regimen, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the AVD Regimen segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Myeloid Leukemia Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Myeloid Leukemia Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Myeloid Leukemia Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Myeloid Leukemia Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Myeloid Leukemia Treatment covered in this report include Ambit Biosciences Corporation, Celgene Corporation, Cephalon, Clavis Pharma, Eisai, Genzyme Corporation and Sunesis Pharmaceuticals, etc.
The global Acute Myeloid Leukemia Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Global Acute Myeloid Leukemia Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Myeloid Leukemia Treatment market, Segment by Type:
DC Regimen
AVD Regimen
VCD Regimen
Global Acute Myeloid Leukemia Treatment market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acute Myeloid Leukemia Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
The global Acute Myeloid Leukemia Treatment market size is expected to reach US$ 1040.9 million by 2029, growing at a CAGR of 7.9% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Myeloid Leukemia Treatment in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Acute Myeloid Leukemia Treatment market. DC Regimen, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the AVD Regimen segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Myeloid Leukemia Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Myeloid Leukemia Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Myeloid Leukemia Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Myeloid Leukemia Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Myeloid Leukemia Treatment covered in this report include Ambit Biosciences Corporation, Celgene Corporation, Cephalon, Clavis Pharma, Eisai, Genzyme Corporation and Sunesis Pharmaceuticals, etc.
The global Acute Myeloid Leukemia Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Global Acute Myeloid Leukemia Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Myeloid Leukemia Treatment market, Segment by Type:
DC Regimen
AVD Regimen
VCD Regimen
Global Acute Myeloid Leukemia Treatment market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acute Myeloid Leukemia Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Acute Myeloid Leukemia Treatment
1.1 Acute Myeloid Leukemia Treatment Market Overview
1.1.1 Acute Myeloid Leukemia Treatment Product Scope
1.1.2 Acute Myeloid Leukemia Treatment Market Status and Outlook
1.2 Global Acute Myeloid Leukemia Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Acute Myeloid Leukemia Treatment Market Size by Region (2018-2029)
1.4 Global Acute Myeloid Leukemia Treatment Historic Market Size by Region (2018-2023)
1.5 Global Acute Myeloid Leukemia Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Acute Myeloid Leukemia Treatment Market Size (2018-2029)
1.6.1 North America Acute Myeloid Leukemia Treatment Market Size (2018-2029)
1.6.2 Europe Acute Myeloid Leukemia Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Acute Myeloid Leukemia Treatment Market Size (2018-2029)
1.6.4 Latin America Acute Myeloid Leukemia Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Acute Myeloid Leukemia Treatment Market Size (2018-2029)
2 Acute Myeloid Leukemia Treatment Market by Type
2.1 Introduction
2.1.1 DC Regimen
2.1.2 AVD Regimen
2.1.3 VCD Regimen
2.2 Global Acute Myeloid Leukemia Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Acute Myeloid Leukemia Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Acute Myeloid Leukemia Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Acute Myeloid Leukemia Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Acute Myeloid Leukemia Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Acute Myeloid Leukemia Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Acute Myeloid Leukemia Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Acute Myeloid Leukemia Treatment Revenue Breakdown by Type (2018-2029)
3 Acute Myeloid Leukemia Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Acute Myeloid Leukemia Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Acute Myeloid Leukemia Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Acute Myeloid Leukemia Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Acute Myeloid Leukemia Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Acute Myeloid Leukemia Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Acute Myeloid Leukemia Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Acute Myeloid Leukemia Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Acute Myeloid Leukemia Treatment Revenue Breakdown by Application (2018-2029)
4 Acute Myeloid Leukemia Treatment Competition Analysis by Players
4.1 Global Acute Myeloid Leukemia Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia Treatment as of 2022)
4.3 Date of Key Players Enter into Acute Myeloid Leukemia Treatment Market
4.4 Global Top Players Acute Myeloid Leukemia Treatment Headquarters and Area Served
4.5 Key Players Acute Myeloid Leukemia Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Acute Myeloid Leukemia Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Ambit Biosciences Corporation
5.1.1 Ambit Biosciences Corporation Profile
5.1.2 Ambit Biosciences Corporation Main Business
5.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Treatment Products, Services and Solutions
5.1.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Ambit Biosciences Corporation Recent Developments
5.2 Celgene Corporation
5.2.1 Celgene Corporation Profile
5.2.2 Celgene Corporation Main Business
5.2.3 Celgene Corporation Acute Myeloid Leukemia Treatment Products, Services and Solutions
5.2.4 Celgene Corporation Acute Myeloid Leukemia Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Celgene Corporation Recent Developments
5.3 Cephalon
5.3.1 Cephalon Profile
5.3.2 Cephalon Main Business
5.3.3 Cephalon Acute Myeloid Leukemia Treatment Products, Services and Solutions
5.3.4 Cephalon Acute Myeloid Leukemia Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Clavis Pharma Recent Developments
5.4 Clavis Pharma
5.4.1 Clavis Pharma Profile
5.4.2 Clavis Pharma Main Business
5.4.3 Clavis Pharma Acute Myeloid Leukemia Treatment Products, Services and Solutions
5.4.4 Clavis Pharma Acute Myeloid Leukemia Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Clavis Pharma Recent Developments
5.5 Eisai
5.5.1 Eisai Profile
5.5.2 Eisai Main Business
5.5.3 Eisai Acute Myeloid Leukemia Treatment Products, Services and Solutions
5.5.4 Eisai Acute Myeloid Leukemia Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Eisai Recent Developments
5.6 Genzyme Corporation
5.6.1 Genzyme Corporation Profile
5.6.2 Genzyme Corporation Main Business
5.6.3 Genzyme Corporation Acute Myeloid Leukemia Treatment Products, Services and Solutions
5.6.4 Genzyme Corporation Acute Myeloid Leukemia Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Genzyme Corporation Recent Developments
5.7 Sunesis Pharmaceuticals
5.7.1 Sunesis Pharmaceuticals Profile
5.7.2 Sunesis Pharmaceuticals Main Business
5.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Treatment Products, Services and Solutions
5.7.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Sunesis Pharmaceuticals Recent Developments
6 North America
6.1 North America Acute Myeloid Leukemia Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Acute Myeloid Leukemia Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Acute Myeloid Leukemia Treatment Market Dynamics
11.1 Acute Myeloid Leukemia Treatment Industry Trends
11.2 Acute Myeloid Leukemia Treatment Market Drivers
11.3 Acute Myeloid Leukemia Treatment Market Challenges
11.4 Acute Myeloid Leukemia Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
